Key Highlights

● Third-quarter Revenue of $524.4 million beat the $499.5 million analyst forecast.

● Brinsupri generated $400.1 million in sales, up strongly from the second quarter.

● Insmed raised the low end of 2026 Brinsupri guidance to $1.35 billion.

● Health care was the best-performing S&P 500 sector as investors rotated out of technology.

Insmed (NASDAQ:INSM)'s new lung-disease drug Brinsupri drove third-quarter revenue well past forecasts, and the company raised its outlook for the product, sending the shares sharply higher on Thursday.

A launch running ahead of plan

Few things excite biotech investors like a new drug that is selling faster than expected. Insmed delivered exactly that on Thursday, October 29.

The company reported third-quarter revenue of $524.4 million, ahead of the $499.5 million analysts had forecast and up dramatically from a year earlier, according to one report. The main driver was Brinsupri, which generated $400.1 million in sales in the quarter, up strongly from the second quarter.

Chief executive Will Lewis said the U.S. launch "continues to exceed expectations," the report said.

The stock climbed sharply on the news. Reports differed on the size of the gain at various points in the session, with one mid-morning figure higher than others, but all described a strong rally.

Raising the bar

Insmed also raised the low end of its 2026 Brinsupri sales guidance to $1.35 billion, keeping the top of the range at $1.4 billion, according to one report. Narrowing the range upward points to a stronger floor for the drug's sales this year.

Another source said the company raised full-year guidance for key products, adding to the sense that the commercial story is gathering pace.

What Brinsupri treats

Brinsupri, known generically as brensocatib, treats non-cystic fibrosis bronchiectasis, a chronic lung condition in which the airways become permanently widened and inflamed. Patients suffer persistent cough, mucus buildup and repeated infections known as flare-ups. Brinsupri works by blocking an enzyme involved in the inflammation that drives the disease.

Before its approval, patients had no approved therapies designed specifically for the condition, which helps explain why Demand has been strong.

Health care led the market

Insmed's rally was part of a broad rush into health care, the best-performing sector in the S&P 500 on Thursday. Eli Lilly (NYSE:LLY) jumped after reporting strong revenue growth and raising its guidance. Merck (NYSE:MRK) climbed after beating estimates and lifting its outlook.

Investors rotated into health care, financials and real estate as they sold mega-cap technology. The Nasdaq Composite tumbled 365.13 points to 26,184.72 as Alphabet (NASDAQ:GOOGL) suffered its worst day since its 2004 IPO. The S&P 500 slipped 23.59 points to 7,720.39, but more than 400 of its members rose.

"There's plenty of other places to go with your money outside of the AI trade that have pretty decent prospects," one market strategist said, according to media reports.

Not every drugmaker rallied. Alnylam (NASDAQ:ALNY) plunged after management indicated demand for its heart drug Amvuttra would not accelerate in the fourth quarter, and Iovance (NASDAQ:IOVA) tumbled on updated lung cancer data. The divergence showed investors rewarding commercial execution and punishing disappointment.

The macro backdrop

Third-quarter GDP grew faster than expected, accelerating from the second quarter, while September PCE Inflation ran hot. Those readings kept a December rate hike from the Federal Reserve firmly in view after the Central Bank held steady on Wednesday in a 10–2 vote.

Health care stocks are often seen as defensive because demand for medicine does not depend heavily on the economic cycle. That quality made them an attractive destination for money leaving technology.

What to watch

The key number for Insmed is Brinsupri's fourth-quarter sales, which will show whether the drug finishes 2026 near the top of its $1.35 billion to $1.4 billion range. Investors will watch prescription trends, patient uptake and any early signs of how the company frames 2027.

Further guidance updates and commentary on international launches will also matter. Broader sector sentiment, shaped by the Fed's December 8–9 meeting and Friday's Employment Cost Index, will help determine whether health care's Leadership holds.